CA2877721A1 - Use of markers in the diagnosis and treatment of prostate cancer - Google Patents
Use of markers in the diagnosis and treatment of prostate cancer Download PDFInfo
- Publication number
- CA2877721A1 CA2877721A1 CA2877721A CA2877721A CA2877721A1 CA 2877721 A1 CA2877721 A1 CA 2877721A1 CA 2877721 A CA2877721 A CA 2877721A CA 2877721 A CA2877721 A CA 2877721A CA 2877721 A1 CA2877721 A1 CA 2877721A1
- Authority
- CA
- Canada
- Prior art keywords
- keratin
- prostate cancer
- level
- filamin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 507
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 504
- 238000003745 diagnosis Methods 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims description 100
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims abstract description 415
- 108010066302 Keratin-19 Proteins 0.000 claims abstract description 412
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 claims abstract description 364
- 108010066330 Keratin-15 Proteins 0.000 claims abstract description 359
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims abstract description 349
- 102000013366 Filamin Human genes 0.000 claims abstract description 346
- 108060002900 Filamin Proteins 0.000 claims abstract description 346
- 108010070507 Keratin-7 Proteins 0.000 claims abstract description 340
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 claims abstract description 300
- 108010066327 Keratin-18 Proteins 0.000 claims abstract description 297
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 claims abstract description 293
- 108010070511 Keratin-8 Proteins 0.000 claims abstract description 287
- 238000000034 method Methods 0.000 claims abstract description 279
- 102100025758 Keratin, type II cytoskeletal 4 Human genes 0.000 claims abstract description 274
- 108010070921 Keratin-4 Proteins 0.000 claims abstract description 272
- 238000012544 monitoring process Methods 0.000 claims abstract description 61
- -1 tubulin-beta 3 Proteins 0.000 claims abstract description 33
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 claims description 394
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 203
- 239000012472 biological sample Substances 0.000 claims description 190
- 239000000523 sample Substances 0.000 claims description 159
- 230000014509 gene expression Effects 0.000 claims description 140
- 239000013068 control sample Substances 0.000 claims description 113
- 239000003550 marker Substances 0.000 claims description 99
- 210000002307 prostate Anatomy 0.000 claims description 55
- 238000001514 detection method Methods 0.000 claims description 50
- 102000004243 Tubulin Human genes 0.000 claims description 47
- 108090000704 Tubulin Proteins 0.000 claims description 47
- 230000001965 increasing effect Effects 0.000 claims description 44
- 101001018021 Homo sapiens T-lymphocyte surface antigen Ly-9 Proteins 0.000 claims description 37
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 36
- 230000002159 abnormal effect Effects 0.000 claims description 36
- 239000003098 androgen Substances 0.000 claims description 35
- 230000003247 decreasing effect Effects 0.000 claims description 31
- 239000003153 chemical reaction reagent Substances 0.000 claims description 27
- 230000008859 change Effects 0.000 claims description 24
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims description 23
- 238000011269 treatment regimen Methods 0.000 claims description 23
- 238000002560 therapeutic procedure Methods 0.000 claims description 21
- 238000002512 chemotherapy Methods 0.000 claims description 15
- 238000001794 hormone therapy Methods 0.000 claims description 14
- 208000023958 prostate neoplasm Diseases 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 14
- 239000000090 biomarker Substances 0.000 claims description 13
- 230000000683 nonmetastatic effect Effects 0.000 claims description 12
- 230000005855 radiation Effects 0.000 claims description 12
- 230000001419 dependent effect Effects 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 8
- 238000009175 antibody therapy Methods 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 238000012512 characterization method Methods 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 38
- 238000004393 prognosis Methods 0.000 abstract description 3
- 101710114141 T-lymphocyte surface antigen Ly-9 Proteins 0.000 description 361
- 102100038358 Prostate-specific antigen Human genes 0.000 description 166
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 83
- 108090000623 proteins and genes Proteins 0.000 description 72
- 206010028980 Neoplasm Diseases 0.000 description 45
- 201000010099 disease Diseases 0.000 description 42
- 238000012360 testing method Methods 0.000 description 42
- 208000035475 disorder Diseases 0.000 description 41
- 230000000771 oncological effect Effects 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 30
- 108010076876 Keratins Proteins 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 102000011782 Keratins Human genes 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 230000007423 decrease Effects 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 108010029485 Protein Isoforms Proteins 0.000 description 18
- 102000001708 Protein Isoforms Human genes 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 101000913551 Homo sapiens Filamin-B Proteins 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 14
- 102100026559 Filamin-B Human genes 0.000 description 13
- 230000004044 response Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 10
- 238000002405 diagnostic procedure Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 230000005751 tumor progression Effects 0.000 description 9
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 101000614439 Homo sapiens Keratin, type I cytoskeletal 15 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 4
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 4
- 101001056466 Homo sapiens Keratin, type II cytoskeletal 4 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 3
- 102000001399 Kallikrein Human genes 0.000 description 3
- 108060005987 Kallikrein Proteins 0.000 description 3
- 101710194919 Keratin, type II cytoskeletal 7 Proteins 0.000 description 3
- 102000007962 Type II Keratins Human genes 0.000 description 3
- 108010089374 Type II Keratins Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 101800000263 Acidic protein Proteins 0.000 description 2
- 206010063075 Cryptogenic cirrhosis Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102000011733 Hair-Specific Keratins Human genes 0.000 description 2
- 108010037031 Hair-Specific Keratins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 2
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 2
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 2
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 2
- 208000013715 atelosteogenesis type I Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000003816 familial cirrhosis Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 210000003963 intermediate filament Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 206010002161 Anal leukoplakia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 201000007708 Boomerang dysplasia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000016758 Congenital fibrosis of extraocular muscles Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710091743 Filamin-A Proteins 0.000 description 1
- 108700037730 Filamin-B Proteins 0.000 description 1
- 101710091745 Filamin-C Proteins 0.000 description 1
- 102100026560 Filamin-C Human genes 0.000 description 1
- 101100233796 Homo sapiens KRT18 gene Proteins 0.000 description 1
- 101000614627 Homo sapiens Keratin, type I cytoskeletal 13 Proteins 0.000 description 1
- 101000973960 Homo sapiens Nucleolar protein 3 Proteins 0.000 description 1
- 101000615933 Homo sapiens Phosphoserine aminotransferase Proteins 0.000 description 1
- 101001096541 Homo sapiens Rac GTPase-activating protein 1 Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 101710183392 Keratin, type I cytoskeletal 15 Proteins 0.000 description 1
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101710194929 Keratin, type II cytoskeletal 4 Proteins 0.000 description 1
- 101710194927 Keratin, type II cytoskeletal 8 Proteins 0.000 description 1
- 201000003599 Larsen syndrome Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 206010024389 Leukoplakia oesophageal Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000004179 Oral Leukoplakia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102300056563 Prostate-specific antigen isoform 1 Human genes 0.000 description 1
- 102300056565 Prostate-specific antigen isoform 3 Human genes 0.000 description 1
- 102300056559 Prostate-specific antigen isoform 4 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000011688 Seminal Vesicle Secretory Proteins Human genes 0.000 description 1
- 108010076335 Seminal Vesicle Secretory Proteins Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 108010011033 Signaling Lymphocytic Activation Molecule Associated Protein Proteins 0.000 description 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108700015968 Slam family Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010072666 White sponge naevus Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000013726 atelosteogenesis type III Diseases 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000004069 complex cortical dysplasia with other brain malformations Diseases 0.000 description 1
- 201000011635 congenital fibrosis of the extraocular muscles Diseases 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000001208 esophageal leukoplakia Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000001722 hereditary mucosal leukokeratosis Diseases 0.000 description 1
- 102000051659 human KRT15 Human genes 0.000 description 1
- 102000044172 human KRT18 Human genes 0.000 description 1
- 102000046414 human KRT19 Human genes 0.000 description 1
- 102000048979 human KRT7 Human genes 0.000 description 1
- 102000052309 human KRT8 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000023127 incomplete bladder emptying Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108010047833 sarcolectin Proteins 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000004032 spondylocarpotarsal synostosis syndrome Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000005040 type I intermediate filament Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665201P | 2012-06-27 | 2012-06-27 | |
| US61/665,201 | 2012-06-27 | ||
| US201261672090P | 2012-07-16 | 2012-07-16 | |
| US61/672,090 | 2012-07-16 | ||
| US201261673094P | 2012-07-18 | 2012-07-18 | |
| US61/673,094 | 2012-07-18 | ||
| US201261702523P | 2012-09-18 | 2012-09-18 | |
| US61/702,523 | 2012-09-18 | ||
| US201261718080P | 2012-10-24 | 2012-10-24 | |
| US201261718081P | 2012-10-24 | 2012-10-24 | |
| US201261718064P | 2012-10-24 | 2012-10-24 | |
| US61/718,064 | 2012-10-24 | ||
| US61/718,080 | 2012-10-24 | ||
| US61/718,081 | 2012-10-24 | ||
| PCT/US2013/048373 WO2014004931A1 (en) | 2012-06-27 | 2013-06-27 | Use of markers in the diagnosis and treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2877721A1 true CA2877721A1 (en) | 2014-01-03 |
Family
ID=49783880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2877721A Abandoned CA2877721A1 (en) | 2012-06-27 | 2013-06-27 | Use of markers in the diagnosis and treatment of prostate cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20140038838A1 (enExample) |
| EP (1) | EP2867375B1 (enExample) |
| JP (2) | JP6352909B2 (enExample) |
| KR (1) | KR20150023904A (enExample) |
| CN (1) | CN104583422A (enExample) |
| AU (1) | AU2013284448B2 (enExample) |
| BR (1) | BR112014032728A2 (enExample) |
| CA (1) | CA2877721A1 (enExample) |
| EA (1) | EA201492284A1 (enExample) |
| ES (1) | ES2720763T3 (enExample) |
| IL (1) | IL236482A0 (enExample) |
| MX (1) | MX360236B (enExample) |
| NZ (1) | NZ703411A (enExample) |
| SG (1) | SG11201408651TA (enExample) |
| WO (1) | WO2014004931A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101933752B1 (ko) | 2012-03-05 | 2018-12-28 | 오와이 아크틱 파트너스 에이비 | 전립선 암의 위험성 및 전립선 부피를 예측하는 방법 및 장치 |
| NZ721962A (en) * | 2014-02-05 | 2022-10-28 | Fujirebio Diagnostics Ab | Composition and method for detecting malignant neoplastic disease |
| ES2964706T3 (es) | 2014-03-28 | 2024-04-09 | Opko Diagnostics Llc | Composiciones y métodos relacionados con el diagnóstico de cáncer de próstata |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| KR102657306B1 (ko) | 2014-12-08 | 2024-04-12 | 버그 엘엘씨 | 전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도 |
| HUE055020T2 (hu) | 2015-03-27 | 2021-11-29 | Opko Diagnostics Llc | Prosztata-antigén szabványok és azok felhasználása |
| WO2017210562A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| WO2018009834A1 (en) * | 2016-07-07 | 2018-01-11 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
| WO2018189292A1 (en) * | 2017-04-13 | 2018-10-18 | Institut National De La Sante Et De La Recherche Medicale | Biomarkers of castration-resistant prostatic cells |
| KR102405789B1 (ko) * | 2018-08-24 | 2022-06-07 | 고려대학교 세종산학협력단 | 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물 |
| CN109608536B (zh) * | 2018-12-12 | 2020-09-15 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用 |
| CN109608537B (zh) * | 2018-12-12 | 2020-09-15 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用 |
| KR102497196B1 (ko) * | 2020-09-08 | 2023-02-07 | (주)유로테크 | 전립선암 진단 점수 계산 방법 및 그 용도 |
| CN114134223B (zh) * | 2021-12-02 | 2022-10-11 | 青岛市中心血站 | 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒 |
| CN114460297A (zh) * | 2022-01-17 | 2022-05-10 | 珠海中科先进技术研究院有限公司 | 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3942999C2 (de) | 1989-12-27 | 1997-12-18 | Progen Biotechnik Gmbh | Verfahren zum Nachweis von malignen Erkrankungen |
| DE4208422A1 (de) | 1992-03-16 | 1993-09-30 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren |
| PT938320E (pt) | 1996-03-26 | 2010-09-22 | Michael S Kopreski | Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro |
| US6107103A (en) * | 1996-10-15 | 2000-08-22 | Procyon Bropharma Inc. | Assay for PSP94 protein |
| WO1999014372A1 (en) | 1997-09-15 | 1999-03-25 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the urinary tract |
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| EP1124572B1 (en) | 1998-10-22 | 2003-09-10 | Curagen Corporation | Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| WO2000040749A2 (en) | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| US7368527B2 (en) | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
| US8410248B2 (en) | 1999-03-12 | 2013-04-02 | Human Genome Sciences Inc. | HWBAO62 polypeptides |
| JP2003535580A (ja) | 2000-03-27 | 2003-12-02 | トーマス ジェファーソン ユニバーシティ | 高特異性マーカー検出 |
| WO2002014500A2 (en) | 2000-08-16 | 2002-02-21 | Chiron Corporation | Human genes and gene expression products |
| AU2002251841A1 (en) | 2001-01-30 | 2002-08-12 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
| US20020137086A1 (en) | 2001-03-01 | 2002-09-26 | Alexander Olek | Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| EP3115470B1 (en) | 2002-03-13 | 2018-07-18 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US20040029151A1 (en) | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| US8076080B2 (en) | 2002-05-21 | 2011-12-13 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
| CA2499843A1 (en) | 2002-09-25 | 2004-04-08 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| US20040109863A1 (en) * | 2002-12-04 | 2004-06-10 | Peter Emtage | Methods of therapy and diagnosis using targeting of cells that express Ly-9 |
| DE10259703A1 (de) | 2002-12-19 | 2004-07-08 | Ivonex Gmbh | Trennungsverfahren |
| JP5479663B2 (ja) | 2002-12-20 | 2014-04-23 | セレラ コーポレーション | 心筋梗塞に関連する遺伝的多型、その検出方法および使用 |
| WO2004076614A2 (de) * | 2003-02-27 | 2004-09-10 | Bernd Hinzmann | Humane nukleinsäuresequenzen aus prostatakarzinomen |
| EP1604014A4 (en) | 2003-03-20 | 2008-03-26 | Dana Farber Cancer Inst Inc | GENE EXPRESSION IN BREAST CANCER |
| CA2527285A1 (en) | 2003-05-28 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| JP2007507204A (ja) | 2003-07-29 | 2007-03-29 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼモデュレーションのバイオマーカー |
| EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| ITPD20030264A1 (it) | 2003-10-30 | 2005-04-30 | Xeptagen Spa | Metodo di diagnosi altamente specifico per neoplasie |
| CN1743849A (zh) | 2004-09-03 | 2006-03-08 | 上海透景生命科技有限公司 | 一种多肿瘤标志物并行检测的方法及试剂盒 |
| US20060057127A1 (en) | 2004-09-10 | 2006-03-16 | Pocheng Liu | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
| US20060063214A1 (en) | 2004-09-17 | 2006-03-23 | Ozge Alper | Methods and compositions for diagnosing neoplastic disease |
| JP2008518610A (ja) | 2004-11-03 | 2008-06-05 | アルマック ダイアグノスティックス リミテッド | トランスクリプトームマイクロアレイ技法およびそれを使用する方法 |
| CA2601157A1 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| EP2270226B1 (en) | 2005-03-31 | 2016-05-18 | Two Cells Co., Ltd | Method for distinguishing mesenchymal stem cell using molecular marker and use thereof |
| US20090186024A1 (en) | 2005-05-13 | 2009-07-23 | Nevins Joseph R | Gene Expression Signatures for Oncogenic Pathway Deregulation |
| WO2006127860A2 (en) | 2005-05-25 | 2006-11-30 | Expression Pathology, Inc. | Multiplex method for increased proteomic coverage from histopathologically processed biological samples using liquid tissue preparations |
| US8609345B2 (en) * | 2005-05-25 | 2013-12-17 | Expression Pathology Incorporated | Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| CA2612021A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1734118A1 (en) | 2005-06-15 | 2006-12-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening |
| US7842466B1 (en) | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
| WO2007047796A2 (en) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070220621A1 (en) | 2005-10-31 | 2007-09-20 | Clarke Michael F | Genetic characterization and prognostic significance of cancer stem cells in cancer |
| US20070122856A1 (en) | 2005-11-10 | 2007-05-31 | Aurelium Biopharma Inc. | Tissue diagnostics for ovarian cancer |
| EP1963860A1 (en) * | 2005-12-19 | 2008-09-03 | University of Hull | Cancer screening test |
| US20070231822A1 (en) | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
| JP4968577B2 (ja) * | 2006-04-11 | 2012-07-04 | エフ．ホフマン−ラ ロシュ アーゲー | サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ |
| US20080003624A1 (en) | 2006-06-13 | 2008-01-03 | Sysmex Corporation | Cancer metastasis determination method |
| WO2008013989A2 (en) | 2006-07-27 | 2008-01-31 | Cell Genesys, Inc. | Methods and compositions for identifying a cellular immune response against prostate cancer |
| EP2057465A4 (en) | 2006-08-09 | 2010-04-21 | Homestead Clinical Corp | ORGANIC PROTEINS AND METHOD OF USE THEREOF |
| US8642349B1 (en) | 2006-08-11 | 2014-02-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial neural network proteomic tumor classification |
| US8748108B2 (en) | 2006-09-05 | 2014-06-10 | Abbvie Inc. | Biomarkers for identifying patient classes |
| EP2064552B1 (en) | 2006-09-07 | 2011-08-31 | Universitätsklinikum Hamburg-Eppendorf | Method for the detection of cancerous epithelial cells using released cytokeratins as markers for said cells |
| US9353415B2 (en) | 2006-12-19 | 2016-05-31 | Thomson Reuters (Scientific) Llc | Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom |
| CA2679664C (en) * | 2007-03-02 | 2017-04-25 | Cell Genesys, Inc. | Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer |
| US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| WO2008121307A2 (en) * | 2007-03-28 | 2008-10-09 | Cell Genesys, Inc. | Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer |
| WO2008144345A2 (en) | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| US20090221004A1 (en) | 2007-06-01 | 2009-09-03 | Anita Lim Hong | Caspase-cleavage anti-keratin antibodies for detection of apoptosis |
| US8889361B2 (en) | 2007-09-19 | 2014-11-18 | The Research Foundation For The State University Of New York | Gene expression signatures in enriched tumor cell samples |
| WO2009045389A2 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20090105167A1 (en) | 2007-10-19 | 2009-04-23 | Duke University | Predicting responsiveness to cancer therapeutics |
| KR101202220B1 (ko) | 2007-12-10 | 2012-11-16 | 에프. 호프만-라 로슈 아게 | 암 마커로서의 세프라아제 |
| EP2245199B1 (en) | 2008-02-01 | 2013-11-13 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
| US8008032B2 (en) | 2008-02-25 | 2011-08-30 | Cellective Dx Corporation | Tagged ligands for enrichment of rare analytes from a mixed sample |
| EP2318543A2 (en) | 2008-07-16 | 2011-05-11 | Dana-Farber Cancer Institute Inc. | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
| US9127078B2 (en) | 2008-07-21 | 2015-09-08 | The Trustees Of The University Of Pennsylvania | Methods and compositions using splicing regulatory proteins involved in tumor suppression |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| IT1391619B1 (it) | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
| JP5172020B2 (ja) | 2008-11-12 | 2013-03-27 | エフ．ホフマン−ラ ロシュ アーゲー | 癌のマーカーとしてのｐａｃａｐ |
| WO2013022995A2 (en) | 2011-08-08 | 2013-02-14 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| WO2010065940A1 (en) * | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| ES2490613T3 (es) | 2008-12-22 | 2014-09-04 | F. Hoffmann-La Roche Ag | ARMET como marcador de cáncer |
| US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| JP2012100536A (ja) | 2009-03-02 | 2012-05-31 | Genescience Co Ltd | 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法 |
| US20110311443A1 (en) | 2009-03-06 | 2011-12-22 | Klaus Tschira Stiftung Ggmbh | Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient |
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| US10815517B2 (en) | 2009-04-28 | 2020-10-27 | Roche Diagnostics Operations, Inc. | Use of DPPIV/seprase as a marker for cancer |
| WO2011040532A1 (ja) * | 2009-10-02 | 2011-04-07 | 学校法人 久留米大学 | 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット |
| US9456558B2 (en) | 2009-10-29 | 2016-10-04 | King Kutter, Inc. | Stump cutter |
| EP2335838B1 (en) | 2009-12-18 | 2012-09-26 | Deutsche Post AG | Sorting system and method using a portable device |
| US20130095503A1 (en) | 2010-01-05 | 2013-04-18 | University Of Cincinnati | Serum spla2-iia as diagnosis marker for prostate and lung cancer |
| US20110177525A1 (en) | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
| US8664472B2 (en) | 2010-04-28 | 2014-03-04 | Sesaco Corporation | Pygmy sesame plants for mechanical harvesting |
| EP2390665A1 (en) * | 2010-05-27 | 2011-11-30 | Atlas Antibodies AB | Prostate cancer biomarkers |
| US8557777B2 (en) | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
| WO2012006634A2 (en) | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| EP2598873A4 (en) * | 2010-07-28 | 2013-11-20 | Metabolon Inc | BIOMARKERS OF PROSTATE CANCER AND METHODS USING THEM |
| US9040464B2 (en) * | 2010-08-16 | 2015-05-26 | Mount Sinai Hosptial | Markers of the male urogenital tract |
| US20140148350A1 (en) * | 2010-08-18 | 2014-05-29 | David Spetzler | Circulating biomarkers for disease |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| US9255142B2 (en) | 2010-09-09 | 2016-02-09 | Beijing Cotimes Biotech Co., Ltd. | Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof |
| US9347953B2 (en) | 2010-12-06 | 2016-05-24 | Thd S.P.A. | Method for the diagnosis of a carcinoma and uses thereof |
| AU2011349101A1 (en) | 2010-12-24 | 2013-05-02 | Map Diagnostics Pty Ltd | Selective reaction monitoring (SRM) derived protein profiles for cancer and other pathologic entities |
| WO2012101283A1 (en) | 2011-01-28 | 2012-08-02 | Biosystems International Sas | Combinatorial biomarkers for clinical applications in lung cancer patient management |
| WO2012116248A1 (en) | 2011-02-24 | 2012-08-30 | Massachusetts Institute Of Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
| KR101320633B1 (ko) | 2011-05-25 | 2013-10-30 | 엠앤디 (주) | 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트 |
| WO2012135397A2 (en) | 2011-03-29 | 2012-10-04 | Lisanti Michael P | Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome |
| WO2012174256A2 (en) | 2011-06-17 | 2012-12-20 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| DK2551673T3 (en) | 2011-07-26 | 2016-05-02 | Univ Salamanca | Methods for detecting cancer infiltration in the central nervous system |
| CA2848162C (en) | 2011-09-12 | 2023-03-14 | Creatics Llc | Non-invasive methods of detecting target molecules |
| US20150152474A1 (en) | 2012-03-09 | 2015-06-04 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| HK1208470A1 (en) | 2012-03-29 | 2016-03-04 | Biogen Ma Inc. | Biomarkers for use in integrin therapy applications |
| US20130317083A1 (en) | 2012-05-04 | 2013-11-28 | Thomas Jefferson University | Non-coding transcripts for determination of cellular states |
| TWI468519B (zh) | 2012-09-05 | 2015-01-11 | Univ China Medical | Methods of detecting squamous cell carcinoma in vitro |
| EP2895864B1 (en) | 2012-09-17 | 2021-03-10 | AIT Austrian Institute of Technology GmbH | Colon cancer diagnostic method and means |
| US9201061B2 (en) | 2013-02-26 | 2015-12-01 | Industry-University Cooperation Foundation Hanyang University | KRT19 stabilizing HER2 and use thereof |
| CA2902841A1 (en) | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| SE538211C2 (sv) | 2013-04-05 | 2016-04-05 | Idl Biotech Ab | Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav |
| US20150079590A1 (en) | 2013-09-18 | 2015-03-19 | Beth Israel Deaconess Medical Center, Inc. | Characterization and analysis of the composition and dynamics of the mammalian riboproteome |
| US10794917B2 (en) | 2013-09-20 | 2020-10-06 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain |
-
2013
- 2013-06-27 WO PCT/US2013/048373 patent/WO2014004931A1/en not_active Ceased
- 2013-06-27 CA CA2877721A patent/CA2877721A1/en not_active Abandoned
- 2013-06-27 NZ NZ703411A patent/NZ703411A/en not_active IP Right Cessation
- 2013-06-27 BR BR112014032728A patent/BR112014032728A2/pt not_active IP Right Cessation
- 2013-06-27 KR KR1020157002289A patent/KR20150023904A/ko not_active Ceased
- 2013-06-27 JP JP2015520541A patent/JP6352909B2/ja not_active Expired - Fee Related
- 2013-06-27 ES ES13809780T patent/ES2720763T3/es active Active
- 2013-06-27 EP EP13809780.3A patent/EP2867375B1/en active Active
- 2013-06-27 CN CN201380045178.1A patent/CN104583422A/zh active Pending
- 2013-06-27 MX MX2015000008A patent/MX360236B/es active IP Right Grant
- 2013-06-27 SG SG11201408651TA patent/SG11201408651TA/en unknown
- 2013-06-27 US US13/929,723 patent/US20140038838A1/en not_active Abandoned
- 2013-06-27 AU AU2013284448A patent/AU2013284448B2/en not_active Ceased
- 2013-06-27 EA EA201492284A patent/EA201492284A1/ru unknown
-
2014
- 2014-12-25 IL IL236482A patent/IL236482A0/en unknown
-
2016
- 2016-03-02 US US15/059,238 patent/US9797905B2/en active Active
-
2017
- 2017-09-15 US US15/706,105 patent/US20180031563A1/en not_active Abandoned
-
2018
- 2018-06-07 JP JP2018109092A patent/JP6581247B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2867375A4 (en) | 2016-06-01 |
| AU2013284448B2 (en) | 2019-04-18 |
| AU2013284448A1 (en) | 2015-01-22 |
| US9797905B2 (en) | 2017-10-24 |
| US20160178632A1 (en) | 2016-06-23 |
| JP2015523569A (ja) | 2015-08-13 |
| US20180031563A1 (en) | 2018-02-01 |
| MX360236B (es) | 2018-10-26 |
| KR20150023904A (ko) | 2015-03-05 |
| MX2015000008A (es) | 2015-04-10 |
| HK1209792A1 (en) | 2016-04-08 |
| BR112014032728A2 (pt) | 2017-11-28 |
| JP2018163164A (ja) | 2018-10-18 |
| CN104583422A (zh) | 2015-04-29 |
| ES2720763T3 (es) | 2019-07-24 |
| NZ703411A (en) | 2017-09-29 |
| EP2867375B1 (en) | 2019-02-27 |
| WO2014004931A1 (en) | 2014-01-03 |
| US20140038838A1 (en) | 2014-02-06 |
| JP6352909B2 (ja) | 2018-07-04 |
| IL236482A0 (en) | 2015-02-26 |
| JP6581247B2 (ja) | 2019-09-25 |
| EP2867375A1 (en) | 2015-05-06 |
| SG11201408651TA (en) | 2015-01-29 |
| EA201492284A1 (ru) | 2015-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9797905B2 (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
| JP6430560B2 (ja) | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ | |
| RU2596394C2 (ru) | Маркеры для рака эндометрия | |
| EP3230314B1 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| WO2005100998A2 (en) | Membrane markers for use in cancer diagnosis and therapy | |
| JP2023533873A (ja) | 癌用の予後バイオマーカー | |
| US9599624B2 (en) | BARD1 isoforms in lung and colorectal cancer and use thereof | |
| US20150377889A1 (en) | Galectin-3 as a marker for prostate cancer | |
| US20150011411A1 (en) | Biomarkers of cancer | |
| KR102731352B1 (ko) | 위암의 예후 예측 방법 | |
| HK1209792B (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
| KR101722836B1 (ko) | 암 발병의 예측, 조기 진단 및 치료제로써의 nkx6.3의 용도 | |
| KR101927577B1 (ko) | 간암 바이오 마커로서 ｈ２ａ．ｚ．１의 용도 | |
| WO2007074341A1 (en) | Detection of oesophageal cancer | |
| HK1245295B (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| HK1245295A1 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180626 |
|
| FZDE | Discontinued |
Effective date: 20220809 |
|
| FZDE | Discontinued |
Effective date: 20220809 |